Dr Agarwal's Hea

Who are the top shareholders of the Dr Agarwal's Hea?

The top shareholders of Dr Agarwal's Hea are primarily Foreign Institutional Investors (FIIs) with 60.62%, led by Hyperion Investments Pte Ltd at 23.17%. Dr. Athiya Agarwal is the largest individual shareholder at 5.99%, while mutual funds hold 3.84% and individual investors own 1.61%.

The top shareholders of Dr Agarwal's Hea include a mix of institutional and individual investors. The majority of the shares are held by Foreign Institutional Investors (FIIs), who own approximately 60.62% of the company. The highest public shareholder is Hyperion Investments Pte Ltd, holding 23.17%. Among individual stakeholders, Dr. Athiya Agarwal is the promoter with the highest holding at 5.99%. Additionally, mutual funds are represented by six schemes, collectively holding 3.84%. Individual investors account for 1.61% of the shares.

Has Dr Agarwal's Hea declared dividend?

No Dividend History Available

Who are the peers of the Dr Agarwal's Hea?

Dr Agarwal's Hea peers include Narayana Hrudaya, Global Health, and Aster DM Health, among others. Key insights show excellent management risk at Global Health and Narayana Hrudaya, with Aster DM Health having the highest 1-year return at 78.92%.

Peers: The peers of Dr Agarwal's Hea are Narayana Hrudaya, Global Health, Aster DM Health., Krishna Institu., Rainbow Child., Jupiter Life Lin, Health.Global, Kovai Medical, Yatharth Hospit.<BR><BR>Quality Snapshot: Excellent management risk is observed at Global Health, Jupiter Life Lin, and Narayana Hrudaya, while Average management risk is found at Aster DM Health., Yatharth Hospit., and the rest. Good growth is seen at Dr Agarwal's Hea, Narayana Hrudaya, and Global Health, while Below Average growth is noted at Aster DM Health., Krishna Institu., and the rest. Excellent capital structure is present at Global Health, Krishna Institu., and Yatharth Hospit., while Below Average capital structure is found at Aster DM Health., Health.Global, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aster DM Health. at 78.92%, while the lowest is Jupiter Life Lin at 11.28%. Dr Agarwal's Hea does not have a 1-year return available for comparison. Additionally, Jupiter Life Lin and Health.Global have negative six-month returns.

What does Dr Agarwal's Hea do?

Dr Agarwal's Health Care Ltd is a mid-cap hospital company established in 2010, with recent quarterly net sales of ₹4,602 Cr and a net profit of ₹326 Cr as of March 2025. Key financial metrics include a P/E ratio of 160.00 and a market cap of ₹13,701 Cr.

Overview:<BR>Dr Agarwal's Health Care Ltd operates in the hospital industry and is categorized as a mid-cap company.<BR><BR>History:<BR>The company was incorporated in 2010 and commenced operations shortly thereafter. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 4,602 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 326 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 13,701 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 160.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.24 <BR>Return on Equity: 4.58% <BR>Price to Book: 7.34 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Dr Agarwal's Hea?

As of 24th July, Dr Agarwals Health Care Ltd has a market capitalization of 13,954.00 Cr, with recent net sales of 1,656.38 Cr and a net profit of 110.24 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Dr Agarwals Health Care Ltd has a market capitalization of 13,954.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,656.38 Cr, while the sum of Net Profit for the same period is 110.24 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 1,339.41 Cr and Total Assets totaling 2,716.13 Cr.

Is Dr Agarwal's Hea overvalued or undervalued?

As of September 12, 2025, Dr Agarwal's Healthcare is considered very expensive and overvalued with a PE ratio of 160.64, significantly higher than its peers, and a low ROE of 4.58%, making it not a compelling investment at its current price of 433.10.

As of 12 September 2025, the valuation grade for Dr Agarwal's Healthcare has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently deemed overvalued, with a PE ratio of 160.64, a Price to Book Value of 7.36, and an EV to EBITDA of 31.07. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Dr Agarwal's Healthcare stands out with a notably higher PE ratio than Max Healthcare, which has a PE of 95.48, and Apollo Hospitals, which is at 71.91. Additionally, the company's ROE is only 4.58%, which is considerably lower than the industry average, further reinforcing the overvaluation narrative. Despite a recent stock return of 1.55% over the past week, which slightly outperformed the Sensex's 1.48%, the overall valuation metrics suggest that Dr Agarwal's Healthcare is not a compelling investment at its current price of 433.10.

How has been the historical performance of Dr Agarwal's Hea?

Dr Agarwal's Hea has shown significant growth over the past three years, with net sales increasing from 1,017.98 Cr in Mar'23 to 1,711.00 Cr in Mar'25, and operating profit rising from 283.86 Cr to 502.40 Cr during the same period, alongside a substantial increase in total assets. Overall, the company demonstrates a solid performance trajectory with rising revenues and profits.

Answer:<BR>The historical performance of Dr Agarwal's Hea shows significant growth in various financial metrics over the past three years.<BR><BR>Breakdown:<BR>Dr Agarwal's Hea has demonstrated a strong upward trend in net sales, increasing from 1,017.98 Cr in Mar'23 to 1,711.00 Cr in Mar'25. Total operating income followed suit, rising from 1,017.98 Cr to 1,711.00 Cr during the same period. The company's total expenditure also grew, reaching 1,254.62 Cr in Mar'25, up from 747.63 Cr in Mar'23. Operating profit (PBDIT) saw a notable increase, climbing from 283.86 Cr in Mar'23 to 502.40 Cr in Mar'25. Profit before tax also improved, moving from 83.59 Cr in Mar'23 to 159.85 Cr in Mar'25, while profit after tax showed a slight fluctuation, peaking at 110.34 Cr in Mar'25 compared to 103.23 Cr in Mar'23. The consolidated net profit remained relatively stable, with a slight increase from 83.06 Cr in Mar'24 to 83.46 Cr in Mar'25. The company's total assets rose significantly from 1,769.72 Cr in Mar'23 to 3,639.60 Cr in Mar'25, reflecting robust growth in shareholder's funds and reserves. Cash flow from operating activities also improved, reaching 360.00 Cr in Mar'25, while cash flow from investing activities remained negative at -750.00 Cr, indicating ongoing investments. Overall, Dr Agarwal's Hea has shown a solid performance trajectory with increasing revenues and profits, alongside a growing asset base.

When is the next results date for Dr Agarwals Health Care Ltd?

The next results date for Dr Agarwals Health Care Ltd is February 3, 2026.

The next results date for Dr Agarwals Health Care Ltd is scheduled for February 3, 2026.

Why is Dr Agarwals Health Care Ltd falling/rising?

As of 07-Feb, Dr Agarwals Health Care Ltd's stock price is at 450.90, down 1.3% after three days of gains, and has underperformed its sector. The stock shows a bearish trend, with decreasing investor participation and significant drops in delivery volume.

As of 07-Feb, Dr Agarwals Health Care Ltd's stock price is falling, currently at 450.90, which reflects a decrease of 5.95 or 1.3%. This decline follows a trend reversal after three consecutive days of gains. The stock has underperformed its sector today by 1.37%. Additionally, it reached an intraday low of Rs 445.1, marking a drop of 2.57%. <BR><BR>Investor participation appears to be decreasing, as evidenced by a significant drop in delivery volume, which fell by 24.6% compared to the 5-day average. While the stock is currently above its 5-day moving averages, it remains below the 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Overall, these factors contribute to the stock's current decline.

Which are the latest news on Dr Agarwal's Hea?